Novartis to pull Valturna in the US
This article was originally published in Scrip
Executive Summary
Novartis is to stop marketing its antihypertensive combination Valturna (aliskiren plus valsartan) in the US from 20 July, it has announced, as the FDA updates the labelling for products containing aliskiren following safety concerns.